• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 潜伏期。

HIV latency.

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Howard Hughes Medical Institute, Baltimore, Maryland 21205, USA.

出版信息

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. doi: 10.1101/cshperspect.a007096.

DOI:10.1101/cshperspect.a007096
PMID:22229121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3234450/
Abstract

HIV-1 can establish a state of latent infection at the level of individual T cells. Latently infected cells are rare in vivo and appear to arise when activated CD4(+) T cells, the major targets cells for HIV-1, become infected and survive long enough to revert back to a resting memory state, which is nonpermissive for viral gene expression. Because latent virus resides in memory T cells, it persists indefinitely even in patients on potent antiretroviral therapy. This latent reservoir is recognized as a major barrier to curing HIV-1 infection. The molecular mechanisms of latency are complex and include the absence in resting CD4(+) T cells of nuclear forms of key host transcription factors (e.g., NFκB and NFAT), the absence of Tat and associated host factors that promote efficient transcriptional elongation, epigenetic changes inhibiting HIV-1 gene expression, and transcriptional interference. The presence of a latent reservoir for HIV-1 helps explain the presence of very low levels of viremia in patients on antiretroviral therapy. These viruses are released from latently infected cells that have become activated and perhaps from other stable reservoirs but are blocked from additional rounds of replication by the drugs. Several approaches are under exploration for reactivating latent virus with the hope that this will allow elimination of the latent reservoir.

摘要

HIV-1 可以在个体 T 细胞水平上建立潜伏感染状态。潜伏感染的细胞在体内很少见,似乎是在 HIV-1 的主要靶细胞——被激活的 CD4(+)T 细胞被感染并存活足够长的时间,恢复到静止的记忆状态时出现的,而这种记忆状态不利于病毒基因表达。由于潜伏病毒存在于记忆 T 细胞中,即使在接受高效抗逆转录病毒治疗的患者中,它也会无限期地持续存在。这种潜伏的病毒库被认为是治愈 HIV-1 感染的主要障碍。潜伏的分子机制很复杂,包括静止的 CD4(+)T 细胞中缺乏关键的宿主转录因子(如 NFκB 和 NFAT)的核形式,缺乏 Tat 和促进有效转录延伸的相关宿主因子,抑制 HIV-1 基因表达的表观遗传变化,以及转录干扰。HIV-1 潜伏库的存在有助于解释接受抗逆转录病毒治疗的患者中极低水平病毒血症的存在。这些病毒是从已被激活的潜伏感染细胞以及其他稳定的病毒库中释放出来的,但被药物阻断了进一步复制的机会。目前正在探索几种激活潜伏病毒的方法,希望这将有助于消除潜伏病毒库。

相似文献

1
HIV latency.HIV 潜伏期。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. doi: 10.1101/cshperspect.a007096.
2
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.长期接受抗逆转录病毒治疗的儿科患者中,1型人类免疫缺陷病毒潜伏库中野生型病毒的持续存在及缺乏时间结构。
J Virol. 2002 Sep;76(18):9481-92. doi: 10.1128/jvi.76.18.9481-9492.2002.
3
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.HIV-1储存库:在抗病毒免疫反应和抗逆转录病毒疗法存在的情况下病毒持续存在的机制
Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665.
4
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.帕比司他对细胞相关HIV RNA和DNA水平及潜伏性HIV感染影响的体内分析。
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.
5
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.从潜伏 HIV-1 的再激活到潜伏库的消除:病毒清除存在多种障碍。
Bioessays. 2013 Jun;35(6):544-52. doi: 10.1002/bies.201200170. Epub 2013 Apr 24.
6
Finding a cure for HIV: will it ever be achievable?寻找治愈 HIV 的方法:这是否可能实现?
J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.
7
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.感染儿童静止CD4(+) T淋巴细胞中存在稳定的HIV-1潜伏储存库。
J Clin Invest. 2000 Apr;105(7):995-1003. doi: 10.1172/JCI9006.
8
Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.2005年抗逆转录病毒疗法的科学依据:病毒储存库与耐药性演变
Top HIV Med. 2005 Aug-Sep;13(3):96-100.
9
Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.根除静息CD4+ T细胞中潜伏性HIV-1的治疗方法。
Curr Top Med Chem. 2016;16(10):1191-7. doi: 10.2174/1568026615666150901114138.
10
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.Tat抑制剂双脱氢皮质抑素A可防止HIV-1从潜伏状态重新激活。
mBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.

引用本文的文献

1
Mechanistic insights and HIV suppression by the BRD4-targeting small molecule ZL0580.靶向BRD4的小分子ZL0580的作用机制及对HIV的抑制作用
bioRxiv. 2025 Aug 14:2025.08.14.670267. doi: 10.1101/2025.08.14.670267.
2
Insights of HIV-1 and HBV transcriptional regulation by viral transactivator Tat and HBx.病毒反式激活因子Tat和HBx对HIV-1和HBV转录调控的见解
Virus Genes. 2025 Aug 12. doi: 10.1007/s11262-025-02176-w.
3
Modeling simian immunodeficiency virus (SIV) latency in primary rhesus macaque CD4 T cells.在恒河猴原代CD4 T细胞中模拟猴免疫缺陷病毒(SIV)潜伏感染
bioRxiv. 2025 Jul 28:2025.04.22.650029. doi: 10.1101/2025.04.22.650029.
4
Genome-wide CRISPR knockout screen identifies activating transcription factor (ATF1) as an activator of HIV gene expression.全基因组CRISPR敲除筛选确定激活转录因子(ATF1)为HIV基因表达的激活剂。
mBio. 2025 Aug 13;16(8):e0055725. doi: 10.1128/mbio.00557-25. Epub 2025 Jul 3.
5
HIV-1 latency: From acquaintance to confidant.HIV-1潜伏:从相识到知己。
J Virus Erad. 2025 May 20;11(2):100597. doi: 10.1016/j.jve.2025.100597. eCollection 2025 Jun.
6
Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.“乘客”假说在HIV病毒库持久性及治愈方面的应用与局限性
J Virol. 2025 Jul 22;99(7):e0071425. doi: 10.1128/jvi.00714-25. Epub 2025 Jun 4.
7
Involvement of lncRNAs NEAT1 and ZBTB11-AS1 in Active and Persistent HIV-1 Infection in C20 Human Microglial Cell Line.lncRNAs NEAT1和ZBTB11-AS1在C20人小胶质细胞系中参与HIV-1的活跃和持续感染
Int J Mol Sci. 2025 May 15;26(10):4745. doi: 10.3390/ijms26104745.
8
Neuroinflammation, Blood-Brain Barrier, and HIV Reservoirs in the CNS: An In-Depth Exploration of Latency Mechanisms and Emerging Therapeutic Strategies.中枢神经系统中的神经炎症、血脑屏障与HIV储存库:潜伏期机制及新兴治疗策略的深入探索
Viruses. 2025 Apr 16;17(4):572. doi: 10.3390/v17040572.
9
Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration.模拟HIV中病毒与免疫动力学之间的相互作用:综述及Mrgsolve实现与探索
Clin Transl Sci. 2025 Feb;18(2):e70160. doi: 10.1111/cts.70160.
10
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.双特异性抗体治疗中自然杀伤细胞的耗竭与抗逆转录病毒治疗中断后缺乏对HIV的控制有关。
Commun Biol. 2025 Feb 14;8(1):236. doi: 10.1038/s42003-025-07651-6.

本文引用的文献

1
HIV-1 pathogenesis: the virus.HIV-1 发病机制:病毒。
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a007443. doi: 10.1101/cshperspect.a007443.
2
Novel cell and gene therapies for HIV.用于 HIV 的新型细胞和基因疗法。
Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a007179. doi: 10.1101/cshperspect.a007179.
3
Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model.宿主基因转录水平和方向对原代细胞模型中 HIV-1 潜伏期的影响。
J Virol. 2011 Jun;85(11):5384-93. doi: 10.1128/JVI.02536-10. Epub 2011 Mar 23.
4
Mechanism(s) of SWI/SNF-induced nucleosome mobilization.SWI/SNF 诱导核小体迁移的机制。
Chembiochem. 2011 Jan 24;12(2):196-204. doi: 10.1002/cbic.201000455. Epub 2010 Oct 28.
5
Primary cell models of HIV latency.HIV 潜伏的原代细胞模型。
Curr Opin HIV AIDS. 2011 Jan;6(1):62-7. doi: 10.1097/COH.0b013e3283412568.
6
The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.HIV 潜伏期的分子生物学:打破和恢复 Tat 依赖性转录回路。
Curr Opin HIV AIDS. 2011 Jan;6(1):4-11. doi: 10.1097/COH.0b013e328340ffbb.
7
Short communication: dynamic constraints on the second phase compartment of HIV-infected cells.简短通讯:对HIV感染细胞第二阶段区室的动态限制
AIDS Res Hum Retroviruses. 2011 Jul;27(7):759-61. doi: 10.1089/AID.2010.0199. Epub 2011 Jan 15.
8
Gene regulation by nucleosome positioning.核小体定位对基因的调控。
Trends Genet. 2010 Nov;26(11):476-83. doi: 10.1016/j.tig.2010.08.003. Epub 2010 Sep 9.
9
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.拉替拉韦强化治疗对接受抗逆转录病毒治疗的 HIV 感染患者低水平残留病毒血症的影响:一项随机对照试验。
PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321.
10
Confining euchromatin/heterochromatin territory: jumonji crosses the line.封闭常染色质/异染色质领域: jumonji 跨越界限。
Genes Dev. 2010 Jul 15;24(14):1465-78. doi: 10.1101/gad.1941010.